Exposure of cells to a dose of ionizing radiation as low as 5 mGy can induce changes in radiation sensitivity expressed by cells exposed to subsequent higher doses at later times. This is referred to as an adaptive effect. We describe a unique survivin-associated adaptive response in which increased radiation resistance or sensitization of cells can be induced by exposure to 5 mGy or to the free radical generating drug Emodin (1,3,8-trihydroxy-6-2 methylanthraquinone), a naturally occurring anthraquinone. The purpose of this study was to determine the role of free radical generating processes in affecting both the intracellular localization of the inhibitor of apoptosis protein survivin and its subsequent effect on radiation response in the presence or absence of the anti-oxidant N-acetyl-L-cysteine (NAC).
methylanthraquinone), a naturally occurring anthraquinone. The purpose of this study was to determine the role of free radical generating processes in affecting both the intracellular localization of the inhibitor of apoptosis protein survivin and its subsequent effect on radiation response in the presence or absence of the anti-oxidant N-acetyl-L-cysteine (NAC).
Experiments were performed using two well characterized murine sarcomas: SA-NH p53 wildtype (WT) and FSa p53 mutant (Mut), grown either in culture or as solid tumors in the right hind legs of C3H mice. Doses of 5 mGy or 50 μM Emodin were used to induce changes in the response of these tumor cells to higher radiation exposures using a multi-dosing paradigm.
Effects on radiation sensitivity were determined for SA-NH and FSa cells as a function of survivin translocation either to the cytoplasm or nucleus in the presence or absence of 10 mM NAC treatment. In vitro survival assays (2 Gy per fraction, two once daily fractions) and tumor growth delay (TGD) (5 Gy per fraction, five once daily fractions) studies were performed. Intracellular localization of survivin was determined by enzyme-linked immunosorbent assay (ELISA) and correlated to survival response and treatment conditions. 2 Gy alone had no effect on intracellular translocation of survivin. When preceded 15 min earlier by 5 mGy or Emodin exposures, survivin became elevated in the cytoplasm of p53 WT SA-NH as compared to the nuclei of p53 Mut FSa cells. SA-NH cells transfected with p53 small interfering RNA (siRNA), in contrast, responded similarly to p53 Mut FSa cells by becoming more radiation sensitive if exposed to 5 mGy prior to each 2 Gy irradiation. In contrast to their respective responses to five once daily 5 Gy fractions, SA-NH tumors were protected by 5 mGy exposures administered 15 min prior to each daily 5 Gy dose as evidenced by a more rapid growth (1.9 day decrease in TGD, P = 0.032), while FSa tumors were sensitized, growing at a much slower rate (4.5 day increase in TGD, P < 0.001). Exposure of SA-NH and FSa tumor cells to 10 mM NAC inhibited the ability of 5 mGy and Emodin to induce intracellular translocation of survivin and the corresponding altered adaptive survival response. The survivin-associated adaptive response can be induced following a multi-dosing scheme in which very low radiation doses are followed shortly thereafter by higher doses consistent with a standard image guided radiotherapy
Introduction
Exposure of cells to a very low radiation dose of 5 mGy prior to irradiation with higher doses can result in an altered radiation response that is generally characterized by an increase over the expected level of survival. Originally described as occurring in human lymphocytes (1) , this phenomenon has been extensively investigated in a wide range of both normal and malignant cell systems (2) (3) (4) (5) . With the development and implementation of ionizing radiationbased imaging such as computerized axial tomography (CAT) for routine use in image guided radiotherapy (IGRT), the potential exists that induction of these responses in malignant cells by very low imaging level doses may affect treatment outcomes (6) . Recently we reported on a novel adaptive response mediated by the inhibitor of apoptosis protein survivin that appears to be induced only following a multi-fraction irradiation scheme (7) . The focus of that study was in assessing the role of elevated survivin levels induced by exposure to doses ranging from 5 to 100 mGy on enhancing the radiation resistance of p53 wild-type (WT) murine and human tumor cells to exposures of 2 Gy. Survivin is found primarily in malignant cells and is a bifunctional protein. It can exhibit different properties depending upon its intracellular location. If located in the cytoplasm, survivin can enhance cellular resistance to stress-inducing agents and increase survival through its ability to inhibit apoptosis as was demonstrated in p53 WT RKO36 human colon carcinoma cells, SA-NH murine sarcoma cells and transformed mouse embryo fibroblast cells (7) . Nuclear localization of survivin, in contrast, is not cytoprotective but rather can enhance apoptosis and is associated with regulation of cellular proliferation and division (8) (9) (10) (11) .
Transport of survivin from the nucleus to the cytoplasm is highly regulated and occurs through the nuclear pore complex. This is facilitated through the association of survivin with the redox sensitive chromosome region maintenance 1 nuclear export protein (CRM-1, exportin 1 or XPO1) and the Ras-related nuclear guanosine 5′-triphosphate binding protein (RanGTP) complex (11) (12) (13) . Its transport into the nucleus from the cytoplasm, however, is not through an active transport process requiring a nuclear import protein complex, but rather is by simple diffusion (14) (15) (16) . Nuclear survivin, in turn, has been reported to be susceptible to accelerated proteosomal degradation resulting in a loss of its cytoprotective properties (17) .
In this study we expand our initial observations regarding the survivin-associated adaptive response to investigate the effects of exposure of murine p53 mutant (Mut) or p53 WT tumor cells to a very low dose of 5 mGy or to the free radical generating anthraquinone Emodin (1,3,8-trihydroxy-6-methylanthraquinone). Emodin was chosen for study because it is a known redox effector capable of acting as a pro-oxidant and generating free radicals. As an effective electron acceptor it can interact intracellularly with molecular oxygen to generate superoxide anion (18) . Emodin is a naturally occurring agent found in the roots and barks of certain plants, molds, lichens, and Chinese herbs (19) . It has been used therapeutically to generate reactive oxygen species (ROS) in several tumor systems and potentiate the anticancer effects of various chemotherapeutic drugs (20, 21) . The focus of this investigation is to characterize the effects of two different ROS generating processes on changes in intracellular survivin localization and the accompanying change in radiation response. Both radiation and Emodin protocols will be utilized in a multi-dose treatment scheme. The SA-NH murine tumor model, capable of both in vitro and in vivo growth, has been extensively investigated in our laboratory regarding the role of manganese superoxide dismutase (SOD2) in mediating a classical very low radiation doseinduced radio-adaptive response (4) and was also used to originally identify and characterize survivin's role in a novel adaptive response expressed in a multi dosing paradigm more reflective of those used in standard radiotherapy treatment protocols (7) . Since the functional loss of wild-type p53 has been associated in a number of different cell lines with not only reduced expression of survivin (15, 16, 22, 23) , but also with downstream ROS production and redox regulation (23) (24) (25) we have expanded our investigation to include a p53 Mut FSa tumor model (murine fibrosarcoma cells with a substitution of methionine for valine at position 169) that has been extensively studied in our laboratory (26) (27) (28) along with SA-NH cells transfected with p53 small interfering RNA (siRNA) (29) . Tumor cells were evaluated under in vitro conditions utilizing a split dose radiation protocol of 2 Gy per fraction separated by 24 h with or without an additional 5 mGy or 50 μM Emodin dose administered 15 min prior in the presence or absence of 10 mM NAC. SA-NH and FSa were also evaluated and compared following a five fraction irradiation scheme of 5 Gy per fraction each separated by 24 h using a tumor growth delay assay.
Materials and Methods

Ethics statement
All animal studies, housing and experiments were carried out with The University of 110 (Invitrogen Life Technologies, Carlsbad, CA) supplemented with 10% fetal bovine serum (FBS; Atlanta Biologicals, Lawrenceville, GA), penicillin (100 units/ml) and streptomycin (100 g/ml) (Invitrogen Life Technologies) as described in detail elsewhere (29) . All cell cultures were maintained at 37 o C in a humidified environment containing 5% CO 2 . For all cell survival experiments, cells were grown to confluence and maintained in confluence for three days. One day prior to all experiments the cells were refed with fresh medium. Under these culture conditions SA-NH cells had a plating efficiency (PE) of 80%, while FSa cells had a PE of 15%.
Drugs
N-acetyl-L-cysteine (NAC) and Emodin were obtained from Sigma-Aldrich, St. Louis, MO. NAC was dissolved in phosphate-buffered saline immediately prior to use at a concentration of 100 mM and sterilized using a 0.2 micrometer syringe filter. Emodin was dissolved in DMSO at a concentration of 100 mM. Cells were treated with 10 mM NAC for 30 min and/or 50 M Emodin for 15 min.
Irradiation conditions
For in vitro studies tumor cells were irradiated with very low doses ranging from 5 to 100 mGy 15 min before exposure to a 2 Gy dose and then 24 h later. In vivo irradiations of SA-NH and FSa tumors were performed on tumor-bearing mice that were placed in lead-shielded cylindrical clear-plastic holders. Their unshielded tumor-bearing right hind legs were secured in place with surgical tape during irradiation. All irradiations were performed using a Philips RT250
x-ray generator with a 1mm copper filter operating at 250 kVp and 15 mA. Dosimetry for the mGy and Gy dose exposures were performed by a board certified member of the Medical Physics faculty in the Department of Radiation and Cellular Oncology at The University of Chicago. Dosimetry procedures involved the use of TLD's placed at various locations in the radiation field to calculate the dose rate under various exposure conditions. For the 2 Gy in vitro and 5 Gy in vivo exposures, the dose rate was 1.33 Gy/min; for 100 mGy and 20 mGy exposures the dose rate was 0.3 Gy/min; and for 5 mGy exposures, the dose rate was 0.05 Gy/min. Exposures were administered daily for 2 consecutive days for all in vitro studies and 5 consecutive days in all tumor growth delay experiments.
Cell survival assay
Immediately following each treatment protocol, cell survival was determined using an in vitro colony forming assay. Cells were counted, diluted, and known numbers seeded into 100-mm tissue culture dishes to allow the development of 100-200 colonies per dish. Colonies of SA-NH and FSa cells were fixed and stained 10 and 14 days later, respectively. Each experiment was repeated three times.
Enzyme-linked immunosorbent assay (ELISA)
Cytoplasmic and nuclear protein was prepared from SA-NH and FSa cells according to a method described in detail elsewhere (30) . Cell pellets were suspended in 400 l ice-cold Buffer 
Western blotting
Total proteins were prepared from both SA-NH and FSa cells using a method described elsewhere (10) . Cells were washed with cold PBS, harvested on ice, and transferred to a 15 ml 
Tumor growth delay measurements
Treatment and measurements began when tumors grew to a minimum volume of 250 mm 3 as measured in three dimensions (length along the right hind leg, width at its widest point, and the height of the tumor measured from the femur to the highest point of the tumor). Tumorbearing mice in the control group were loaded into the animal holding chamber with their hind legs taped to the chamber for the same amount of time that the tumor-bearing mice in the irradiation groups were secured. Animals in all experimental groups were sacrificed when tumors reached an approximate volume of 1000 mm 3 .
Statistical Analysis
Means and standard errors were calculated for all data points from at least three independent experiments. Pairwise comparisons of survivin protein concentrations and cell survival between each of the experimental conditions were performed using a Student's twotailed t test (SigmaPlot software 11.0, SPSS, Chicago, IL). Mean tumor volumes over time were compared among groups using repeated measures analysis of covariance (ANOVA) assuming a quadratic model and accounting for separate variances in each group. Post-hoc pairwise comparisons among groups were done using the Tukey-Kramer method (32). Absolute tumor growth delay values, defined as the time in days for the tumors in the treated groups to grow from 250 mm 3 to 1000 mm 3 minus the time in days for untreated control tumors to grow across this same size range, were also determined (29) .
Results
The effect of a very low radiation dose (5 mGy) administered in the presence or absence of 10 mM NAC on SA-NH and FSa cell survival and associated intracellular translocation of survivin in a split dose paradigm
The SA-NH murine sarcoma which is p53 WT expresses a pro-survival adaptive response that is mediated by survivin and characterized by an increase in radiation resistance (7, 33) . Presented in Fig. 1 Total phosphorylated survivin levels, however, appeared to be similar between both cell systems at that time.
Effect of adaptive responses on tumor growth delay
To assess the potential magnitude of the survivin-associated adaptive response following a multiple dosing protocol under in vivo conditions, we performed tumor growth delay studies on SA-NH and FSa tumors that were grown in the right hind legs of C3H mice. Because mouse tumors are relatively aggressive and require substantial radiation dosing to observe effects before animals either die or are required to be euthanized, the two radiation protocols that were used involved exposing mice to five 5 Gy doses each separated by 24 h, with or without the addition of 5 mGy exposures administered 15 min prior to each therapeutic dose.
When tumors reached a volume of 250 mm 3 irradiations were initiated. After tumors grew to a volume of 1000 mm 3 , animals were removed from the study and sacrificed. As demonstrated in Fig. 7 (A) , 5 mGy delivered before each 5 Gy dose to SA-NH tumors induced elevated radiation resistance as manifested by a significant reduction in tumor growth delay of 1.9 days compared to that for tumors irradiated only with 5 Gy doses (P < 0.001 for 5 mGy + 5 Gy compared to 5
Gy only). Under these same conditions, FSa tumors had an increase in tumor growth delay of about 4.5 days, reflecting an increased radiation sensitivity induced by 5 mGy (see Fig. 7 B) .
Absolute growth delay values are presented for comparison in Table 2 .
Discussion
Exposure to a very low dose of a stress-inducing agent such as ionizing radiation results in the increased tolerance of the exposed organism to a subsequent much larger dose. This is referred to as an adaptive response. Most studies on adaptive responses have focused on the use of a single exposure to a very low dose of ionizing radiation followed at a later time by a much larger radiation dose (1) (2) (3) (4) (5) . Underlying this response are redox driven processes that involve the generation and amplification of ROS-mediated signals and the activation of redox sensitive proteins such as tumor necrosis factor  (TNF), nuclear factor kappa B (NFB), and SOD2 (3-5). The discovery of the survivin-associated adaptive response represents a new expression of this redox driven phenomenon, which as a result of its bifunctional properties dependent upon its intracellular localization, can be manifested as conferring either enhanced radiation resistance or sensitization (7, 33) .
Two ROS generating agents, very low dose ionizing radiation and the drug Emodin (18-21), were found to be effective in altering cellular radiation sensitivity to higher radiation doses in tumor cells differing in their p53 mutational status and in inducing the translocation of survivin into the subcellular compartments consistent with these changes in radiation sensitivity (see Figs. 1-4) . The tumor suppressor protein p53 is a redox responsive transcription factor that among other things can regulate cellular ROS generation (24, 25) . It has been reported that WT p53 is a potent suppressor of transforming growth factor- (TGF--induced nicotinamide adenine dinucleotide phosphate oxidase 4 (NOX4) ROS production in lung and breast epithelial cells, while mutant p53 has been associated with enhanced NOX4 expression and elevated levels of ROS production (22) . Enhanced ROS production has also been correlated with a down regulation of survivin and its migration from the cytosol to the nucleus of cells, suggesting that mutation or inhibition of p53 could inhibit a radioprotective adaptive response and possibly even convert it into a radiation sensitization response (23) . Transfection of p53 WT SA-NH cells with p53 siRNA appeared to lead to just such a change in radiation response (see Fig. 5 ). The robust 5 mGy-induced radioadaptive protective response in the WT cells (P < 0.001) was converted into a significant radiosensitization response (P = 0.003) following knockdown of WT p53.
The relative distribution of survivin between the cytoplasm and nucleus was similar and unchanged for both unirradiated control cells and cells exposed to only two 2 Gy doses in both tumor models. Translocation of survivin was observed to occur only when cells were exposed to Survivin is a bifunctional protein whose mode of action is dependent upon its intracellular localization (11) . Survivin is a nuclear cytoplasmic shuttling protein that has an active nuclear exportation signal (NES) in its linker region but lacks a nuclear importation signal (NIP) (8) (9) (10) (11) (12) .
Its movement into the nucleus is not through an active nuclear import process, but rather appears to occur through simple diffusion. Nuclear survivin is subject to accelerated proteosomal degradation, further diminishing any potential for a cytoprotective adaptive response (17) . This suggests that the basis for the observed bifunctional survivin-associated adaptive response induced by very low dose irradiation is dependent upon the underlying nuclear export process responsible for the cytoplasmic translocation of survivin, e.g., the CRM-1 nuclear export protein. Western blots presented in Fig. 6 show a fairly uniform distribution of total phosphorylated survivin under all treatment conditions and between both tumor cell systems. Total CRM-1, in contrast, appears to be uniform regardless of treatment but is observed to be relatively higher in SA-NH as compared to FSa cells. CRM-1 is known to be highly responsive to changes in oxidative stress, with increased ROS resulting in the inhibition of its nuclear transport activity (12, 13) . Mut p53 has been associated with increased oxidative stress in human lung and breast epithelial cells (22) . The relationship between p53 status and intracellular ROS production may, therefore, play an important role in affecting CRM-1 activity and be a determining factor in the redox driven process that drives the survivin-associated adaptive response to be either a cyto-protecting or sensitizing phenomenon (24, 25) . This is supported by the cytoplasmic to nuclear survivin concentration ratios that were calculated for SA-NH and FSa contained in Table 1 is reasonable to suggest that subsequent changes in the intracellular redox environment underlies both survivin-associated adaptive responses (see Table 1 ). A model describing the proposed survivin-associated pro-survival and sensitizing adaptive responses is presented in Fig. 8 .
Since the survivin-associated adaptive response is only demonstrable in a multiple dosing protocol and changes in survival, as measured under in vitro conditions, range from 10 to 20%, it was not clear whether these differences represented the maximum effect that could be attained or whether such differences could be propagated with additional doses of radiation.
To address this issue, tumor growth delay studies were performed in vivo using both tumor models in which five 5 Gy doses were administered 24 h apart with or without 5 mGy doses given 15 min earlier. Under these conditions, the addition of 5 mGy exposures to the treatment protocols resulted in the robust expression of both the radio-protecting and sensitizing adaptive responses. SA-NH tumors exhibited a significant reduction in tumor growth delay of 1.9 days (P = 0.032) (see Fig. 7 A) , while FSa tumors experienced an increase in growth delay of 4.5 days (P < 0.001) (see Fig. 7 B) . The tumor growth parameters and associated statistical significance are included in Table 2 for comparison and demonstrate that the respective survivin-associated prosurvival and sensitization adaptive responses for these two tumors were highly significant and suggestive of being propagated with each dosing fraction in a multi-fraction exposure protocol.
The classical adaptive response paradigm most often described involves exposure of cells to a single very low dose of ionizing radiation prior to a second exposure to a much larger dose at a later time (3) (4) (5) . The kinetics of increased intracellular SOD2 induced by the very low radiation dose generally correlated with the increased magnitude of cell survival measured as a function of the time following when the higher challenge dose was administered. Other factors that were identified as important in this process included an intact and functioning TNFα signaling pathway, activation of NFB and enhanced SOD2 gene expression (3) (4) (5) . It was expected that these factors would also be involved if an adaptive response were expressed in a multiple dosing paradigm. However, when very low radiation doses were administered shortly before or following exposure to high doses delivered over 24 h intervals, neither TNF nor SOD2 were found to be involved (7). Rather, this novel adaptive response was found to be mediated through the action of the tumor specific protein survivin. The uniqueness of the survivin-mediated adaptive response is the potential to exert either a pro-survival or a sensitization phenomenon depending upon the intracellular localization and the associated bifunctional properties of the survivin protein. That this process is redox driven is not unexpected given that the major molecular factors identified as being involved are known to be susceptible to changes in oxidative stress. These include p53, CRM-1, and the bifunctional inhibitor of apoptosis protein survivin. Since survivin is not found in differentiated normal tissues, but rather in malignant tissues, a better understanding of its properties and their dependence upon oxidative stress offers the potential for developing novel methods for enhancing tumor response to therapies while minimizing the probabilities of adversely enhancing tumor resistance.
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